BMS at the 62nd ASH Annual Meeting and Exposition
Critical research driving progress for people with blood cancers
Intended for scientific audiences only.
he American Society of Hematology Annual Meeting and Exposition (ASH) is the premier event in malignant and non-malignant hematology, and despite this year’s challenges, we remain ever-committed to sharing the latest advances and providing continued support as we continue to navigate the COVID-19 pandemic. We look forward to highlighting the depth and diversity of our hematology development program and potential new advances for people living with a range of blood cancers.
Our Data at ASH
Read more about our key data being presented at ASH.
- QUAZAR® AML-001: Analyses from pivotal study of Onureg® (azacitidine tablets; CC-486) in adults with acute myeloid leukemia in first remission
- TRANSCEND and OUTREACH: Data evaluating potential of lisocabtagene maraleucel (liso-cel), in types of leukemia and lymphoma
- CRB-401 and KarMMA: Results highlighting anti-BCMA CAR T therapy idecabtagene viclueucel (ide-cel) in relapsed and refractory multiple myeloma
- Preview the depth and diversity of Bristol Myers Squibb data at ASH across multiple myeloma, lymphoma and myeloid diseases
We are working every day to advance blood cancer treatments that have transformational potential. Learn about our recent advances and what we have on the horizon.
Years before Josh Hansen, director of chemistry at Bristol Myers Squibb’s San Diego R&D site, found his calling in biopharma researching protein degradation, he had his sights set on a career in education. Read more about the important science being done in Josh’s lab.
We are committed to improving the lives of patients and raising awareness of hard-to-treat blood cancers. Learn more here.
Hear from Chief Medical Officer Samit Hirawat, M.D., on how Bristol Myers Squibb has helped patients overcome barriers to clinical trial participation and advanced its R&D pipeline during the global pandemic.
Beta-thalassemia is a blood disorder, with more than 60,000 infants born worldwide with the disease each year. However, unless you live in Asia, India, the Middle East or the Mediterranean where beta-thalassemia is most prevalent, you may never have heard of this inherited blood disorder that disrupts the body’s ability to make hemoglobin.
Possibly the only thing more frightening than being diagnosed with cancer is learning you have a form of the disease you’ve never heard of. Patients with MDS— a little-known blood cancer— are searching for new Multidysplastic Syndrome treatment options.
Our Dedication to Advancing Cell Therapy, A Novel Personalized Medicine
Cell therapy, which includes therapies comprised of cells that are injected, implanted or grafted to treat disease, and use engineered cells to unlock new potential in the fight against cancer, is one of several key areas of research at Bristol Myers Squibb. Learn more about our dedication to cell therapies and personalized medicine here.
Fulfilling the promise of cell therapy requires continued innovation, which is why researchers at Bristol Myers Squibb are relentlessly pursuing a multitude of diverse, next-generation approaches in cell therapy. Learn more about how Bristol Myers Squibb is investing in cell therapy research and using translational data to advance the science for patients.
Kristen Hege, Senior Vice President of Early Clinical Development, Hematology/Oncology & Cell Therapy, shares how patients and physicians can stand to learn from each other, especially with novel treatments like CAR T cell therapy, where practical information is still being refined. Read more about Kristen’s experience and ongoing pursuit to empower her patients.
Our research at ASH this year spans multiple myeloma, lymphoma and myeloid diseases, and multiple therapeutic modalities. Learn more about some of them below.